Cargando…

Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models

Targeted, catalytic degradation of oncoproteins using heterobifunctional small molecules is an attractive modality, particularly for hematologic malignancies, which are often initiated by aberrant transcription factors and are challenging to drug with inhibitors. BRD4, a member of the bromodomain an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Danlin, Nikonova, Anna S., Zhang, Peishan, Deneka, Alexander Y., Fitzgerald, Mark E., Michael, Ryan E., Lee, Linda, Lilly, Anna C., Fisher, Stewart L., Phillips, Andrew J., Nasveschuk, Christopher G., Proia, David A., Tu, Zhigang, Golemis, Erica A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Small Molecule Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338762/ https://www.ncbi.nlm.nih.gov/pubmed/34045230 http://dx.doi.org/10.1158/1535-7163.MCT-20-0831

Ejemplares similares

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer
por: Mirzapoiazova, Tamara, et al.
Publicado: (2021)

Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent
por: Jernigan, Finith, et al.
Publicado: (2021)

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
por: Peng, Peng, et al.
Publicado: (2023)

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
por: Piovesan, Dana, et al.
Publicado: (2022)

Small-Molecule–Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death
por: Avelar, Rita A., et al.
Publicado: (2023)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
por: Hamilton, Erika P., et al.
Publicado: (2023)

APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
por: Xie, Xuqin, et al.
Publicado: (2023)

Characterization of Novel α-Mangostin and Paeonol Derivatives With Cancer-Selective Cytotoxicity
por: Nunna, Suneetha, et al.
Publicado: (2022)

Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
por: Awasthi, Niranjan, et al.
Publicado: (2022)

Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways
por: Scotto, Luigi, et al.
Publicado: (2021)

Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway
por: Zhang, Wei, et al.
Publicado: (2021)

Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
por: Simoneau, Antoine, et al.
Publicado: (2023)

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021)

Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer
por: Alečković, Maša, et al.
Publicado: (2023)

High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer
por: Mizuno, Sho, et al.
Publicado: (2023)

Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
por: Li, Chengxun, et al.
Publicado: (2023)

T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer
por: Li, Dandan, et al.
Publicado: (2021)

Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability
por: Gilbert, Sophie, et al.
Publicado: (2022)

PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer
por: Wu, Cheng, et al.
Publicado: (2021)

Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy
por: Sinnett-Smith, James, et al.
Publicado: (2022)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer
por: Thongchot, Suyanee, et al.
Publicado: (2022)

Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death
por: Jenkins, Laura J., et al.
Publicado: (2023)

Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
por: Furman, Craig, et al.
Publicado: (2022)

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
por: Tran, Khanh B., et al.
Publicado: (2022)

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers
por: Tien, Amy H., et al.
Publicado: (2022)

Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
por: Scherrer, Didier, et al.
Publicado: (2022)

Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents
por: Jo, Ukhyun, et al.
Publicado: (2021)

Upregulation of Somatostatin Receptor Type 2 Improves (177)Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
por: Sharma, Rupali, et al.
Publicado: (2023)

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
por: Rice, William G., et al.
Publicado: (2022)

Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor
por: Lemberg, Kathryn M., et al.
Publicado: (2023)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
por: Wang, Yifei, et al.
Publicado: (2022)

DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models
por: Jiang, Yanyan, et al.
Publicado: (2021)

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
por: Ekstrom, Thomas L., et al.
Publicado: (2021)

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development
por: Gill, Sonja J., et al.
Publicado: (2021)

Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
por: Shagisultanova, Elena, et al.
Publicado: (2022)

Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects
por: Ureshino, Hiroshi, et al.
Publicado: (2021)

Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4q7m01mptakj9dsj79jkfrdiq8